BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Up the bladder ladder, Engene tweak means phase II bell rung
Engene Holdings Inc.’s protocol amendment to its phase II trial with detalimogene voraplasmid in bladder cancer worked out in a big way, and shares of the firm closed Nov....

More in BioWorld

BioWorld MedTech

CLOSURE-AF study not the end of the line for LAAC devices
At first glance, the results of the CLOSURE-AF study would seem to spell doom for left atrial appendage closure devices for patients at risk of stroke, but there is some...

More in BioWorld MedTech

BioWorld Science

UK launches strategy to replace animals in research as scientists voice concern
The U.K. government has published a road map for phasing out animal testing in life sciences research and announced £75 million (US$98.6 million) for work to develop...

More in BioWorld Science

BioWorld Asia

Lilly moves deeper into RNAi with $1.2B Sanegene obesity deal
In a deal worth $1.2 billion, Suzhou Sanegene Bio Inc. and Eli Lilly and Co. are partnering to advance RNAi candidates for metabolic diseases based on Sanegene's tissue...

More in BioWorld Asia

BioWorld Insider Podcast

Bioxcel Therapeutics Inc.’s phase III results in bipolar disorders or schizophrenia could bring Igalmi (BXCL-501) out of the clinic and into patients' homes for easier treatment.